An Open-label Study to Evaluate the Long-term Safety of BCX9930 Monotherapy in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Previously Received BCX9930 in a BioCryst-sponsored Study
Latest Information Update: 05 Sep 2024
At a glance
- Drugs Pelecopan (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions
- Sponsors BioCryst Pharmaceuticals
Most Recent Events
- 05 Sep 2024 This trial has been completed in Hungary, according to European Clinical Trials Database record.
- 13 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 18 Jan 2023 New trial record